Osong Public Health and Research Perspectives

Original Articles

The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures: Munjae Lee, Mankyu Choi; Osong Public Health Res Perspect. 2015;6(5):302-309. Published online October 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.10.013

4,019 View
25 Download
26 Crossref

Objectives
This study analyzes the influence of the financial structure of pharmaceutical companies on R&D investment to create a next-generation profit source or develop relatively cost-effective drugs to maximize enterprise value.
Methods
The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association (KLCA), and data related to stock price is extracted from KISVALUE-Ⅲ of NICE Information Service Co., Ltd. Stata 12.0 was used as the statistical package for panel analysis.
Results
The current ratio had a positive influence on R&D investment, the debt ratio had a negative influence on R&D investment, and return on investment and net sales growth rate did not have a significant influence on R&D investment.
Conclusion
It was found in this study that the higher liquidity ratio, the greater the R&D investment. The stability of pharmaceutical companies has a negative influence on R&D investment. This finding is consistent with the prediction that if a company faces a financial risk, it will be passive in R&D investment due to its financial difficulties.

Citations

Citations to this article as recorded by

Does Business Group Affiliation Enhance Firm-level Innovation? Evidence from Indian Automotive Components Industry
J. Vineesh Prakash, D. K. Nauriyal
The Indian Economic Journal.2025; 73(2): 217. CrossRef
Assessment of Local Pharmaceutical Manufacturing Sector in a Low-income Country: A Descriptive Study
Tesfa Marew, Anteneh Belete, Frances J. Richmond, Tsige Gebre-Mariam
Therapeutic Innovation & Regulatory Science.2025; 59(2): 379. CrossRef
Maliyet Yapışkanlığı Kavramı: Borsa İstanbul 30 Endeksinde Yer Alan Şirketler Üzerinde Bir Uygulama
Sevgi Cengiz
Verimlilik Dergisi.2024; 58(4): 573. CrossRef
Tác động của quản lý vốn lưu động đến đầu tư nghiên cứu và phát triển
Liên Lê Quỳnh
Tạp chí Khoa học Thương mại.2024; : 76. CrossRef
How Indian Pharma Industry Performed in the Last Decade? Impact of a Non-macroeconomic Variable and Financial Distress
Pooja Singh, Anindita Chakraborty
Jindal Journal of Business Research.2023; 12(2): 143. CrossRef
How structural changes are driving R&D activity in India’s pharmaceutical sector
Niloufer Sohrabji, Kristen Marquette
Journal of Pharmaceutical Health Services Research.2023; 14(3): 256. CrossRef
Patent and Marketing Exclusivities 101 for Drug Developers
Bryan Oronsky, Scott Caroen, Franck Brinkhaus, Tony Reid, Meaghan Stirn, Raj Kumar
Recent Patents on Biotechnology.2023; 17(3): 257. CrossRef
The driving process of technological innovation in construction: a firm-level CDM analysis
Zheng Gong, Nannan Wang
Construction Innovation .2022; 22(2): 222. CrossRef
Envisioning the challenges of the pharmaceutical sector in the Indian health-care industry: a scenario analysis
Giuseppe Festa, Ashutosh Kolte, Maria Rosaria Carli, Matteo Rossi
Journal of Business & Industrial Marketing.2022; 37(8): 1662. CrossRef
Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design
Yu-Fei Hua, Jin Lu, Bing Bai, Han-Qing Zhao
Frontiers in Public Health.2022;[Epub] CrossRef
Ambidexterity's influence on export strategy development—The case of the Indian pharmaceutical industry
Ashutosh Kolte, Giuseppe Festa, Matteo Rossi, Alkis Thrassou, Demetris Vrontis, Michael Christofi
Thunderbird International Business Review.2022; 64(5): 465. CrossRef
Local pharmaceutical research and development capacity in a developing country: a qualitative exploration of perspectives from key stakeholders in Ethiopia
Muluken Nigatu Selam, Samuel Abera, Helen Geremew, Eskinder Eshetu Ali
Journal of Pharmaceutical Policy and Practice.2022;[Epub] CrossRef
Optimization and Quest of HPMC loaded Stavudine Controlled Release Dosage Development by Central Composite Design utilizing Reduced Factorial Screening Technique
Jyothsna Gangolu, Sandyapakula Balaiah, Sisir Nandi, Harekrishna Roy
Brazilian Journal of Pharmaceutical Sciences.2022;[Epub] CrossRef
The contribution of intellectual capital to financial stability in Indian pharmaceutical companies
Giuseppe Festa, Matteo Rossi, Ashutosh Kolte, Luca Marinelli
Journal of Intellectual Capital.2021; 22(2): 337. CrossRef
Factors affecting profitability of pharmaceutical company: an Indonesian evidence
Harianto Lim, Rofikoh Rokhim
Journal of Economic Studies.2021; 48(5): 981. CrossRef
Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model
Jingyuan Yang, Ling Wang, Ziyuan Sun, Fangming Zhu, Yihui Guo, Yan Shen
International Journal of Environmental Research an.2021; 18(21): 11560. CrossRef
Drivers of ICT investments in bakery and sugar confectionery processed food sub-sector in India
Navyashree GR, Savita Bhat
Journal of Agribusiness in Developing and Emerging.2020; 10(2): 191. CrossRef
Gouvernance et intensité d’innovation dans les ETI innovantes
Léopold Djoutsa Wamba, Éric Braune, Frédéric Teulon
Management & Avenir.2020; N° 118(4): 111. CrossRef
MALİYET YAPIŞKANLIĞININ YENİDEN GÖZDEN GEÇİRİLMESİ: BORSA İSTANBUL İMALAT SANAYİ ÖRNEĞİ
Mehmet Emin KARABAYIR
Muhasebe ve Vergi Uygulamaları Dergisi.2019; 12(2): 317. CrossRef
Bioaugmentation effect of Aeromonas hydrophila and Pseudomonas putida on kinetics of activated sludge process in treating pharmaceutical industrial wastewater
Marija Vuković Domanovac, Monika Šabić Runjavec, Ernest Meštrović
Journal of Chemical Technology & Biotechnology.2019; 94(8): 2721. CrossRef
Replicating the R&D investments and financial structure relationship: evidence from Borsa İstanbul
Nasif Ozkan
Management Review Quarterly.2018; 68(4): 399. CrossRef
Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry
Shilpi Tyagi, D. K. Nauriyal, Rachita Gulati
Review of Managerial Science.2018; 12(1): 167. CrossRef
Impact of investment in intangible assets on corporate performance in India
Aparna Bhatia, Khushboo Aggarwal
International Journal of Law and Management.2018; 60(5): 1058. CrossRef
Relation of R&D expense to turnover and number of listed companies in all industrial fields
Jun-Hwan Park, Bangrae Lee, Yeong-Ho Moon, GyuSeok Kim, Lee-Nam Kwon
Journal of Open Innovation: Technology, Market, an.2018; 4(1): 1. CrossRef
Policy to encourage the development of antimicrobials
Ayman Chit, Paul Grootendorst
International Journal of Health Governance.2018; 23(2): 101. CrossRef
O IMPACTO DOS INVESTIMENTOS EM P&D NO DESEMPENHO DAS EMPRESAS: APLICAÇÕES NO USO DE REGRESSÃO QUANTÍLICA COM VARIÁVEIS INSTRUMENTAIS
Leonardo Andrade Rocha, Ahmad Saeed Khan, Patrícia Verônica Pinheiro Sales Lima, Maria Ester Soares Dal Poz, Carlos Alano Soares de Almeida
Revista de Economia Contemporânea.2018;[Epub] CrossRef

Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea: Munjae Lee; Osong Public Health Res Perspect. 2015;6(4):249-255. Published online August 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.07.003

3,993 View
28 Download
4 Crossref

Abstract PDF

Objectives
The purpose of this study is to analyze the influence of the corporate governance of pharmaceutical companies on research and development (R&D) investment.
Methods
The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general, and internal transactions were extracted from TS-2000 of the Korea Listed Company Association. Sample firms were those that belong to the medical substance and drug manufacturing industries. Ultimately, 786 firm-year data of 81 firms were included in the sample (unbalanced panel data).
Results
The shareholding ratio of major shareholders and foreigners turned out to have a statistically significant influence on R&D investment (p < 0.05). No statistical significance was found in the shareholding ratio of institutional investors and the ratio of outside directors.
Conclusion
The higher the shareholding ratio of the major shareholders, the greater the R&D investment. There will be a need to establish (or switch to) a holding company structure. Holding companies can directly manage R&D in fields with high initial risks, and they can diversify these risks. The larger the number of foreign investors, the greater the R&D investment, indicating that foreigners directly or indirectly impose pressure on a manager to make R&D investments that bring long-term benefits.

Citations

Citations to this article as recorded by

EFFECT OF CORPORATE GOVERNANCE PRACTICES ON R&D AND INNOVATION COSTS: A CASE STUDY ON BORSA İSTANBUL
Hüseyin Ali KUTLU, Bekir GEREKAN
Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 967. CrossRef
Corporate governance and the environment in the health sector: Systematic literature review
Isabel Cristina Panziera Marques, Zélia Maria da Silva Serrasqueiro Teixeira, Fernanda Maria Duarte Nogueira
Journal of Governance and Regulation.2020; 9(2): 8. CrossRef
Gouvernance et intensité d’innovation dans les ETI innovantes
Léopold Djoutsa Wamba, Éric Braune, Frédéric Teulon
Management & Avenir.2020; N° 118(4): 111. CrossRef
Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms
Chie Hoon Song, Jens Leker
Technology Analysis & Strategic Management.2019; 31(2): 169. CrossRef

Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea: Munjae Lee, Mankyu Choi; Osong Public Health Res Perspect. 2015;6(4):241-248. Published online August 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.07.001

4,107 View
23 Download
17 Crossref

Abstract PDF

Objectives
The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value.
Methods
The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis.
Results
In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t–2 and t–5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t–1, t–3, and t–4, respectively) were not statistically significant.
Conclusion
R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

Citations

Citations to this article as recorded by

R&D investment and corporate total factor productivity under the heterogeneous environmental regulations: evidence from Chinese micro firms
X. Ding, Y. Zhang, Y. Fu, Z. Xu
International Journal of Environmental Science and.2025; 22(2): 753. CrossRef
Impact of Chinese environmental protection tax law on high-pollution firms' employment growth - A quasi natural experiment
Yunshu Shao, Yuxiang Cheng
Economic Analysis and Policy.2025; 86: 416. CrossRef
A new perspective for European SMEs’ innovative support analysis: Does non-financial support matter?
Solomon Gyamfi, Wolfgang Gerstlberger, Viktor Prokop, Jan Stejskal
Heliyon.2024; 10(1): e23796. CrossRef
Lead–lag effect of research between conference papers and journal papers in data mining
Yue Huang, Runyu Tian
WIREs Data Mining and Knowledge Discovery.2024;[Epub] CrossRef
R&D activity and firm performance: mapping the field
Kseniia Boiko
Management Review Quarterly.2022; 72(4): 1051. CrossRef
Pharmaceutical industry in export marketing: a closer look at competitiveness
Mehdi Mohammadzadeh, Nima Bakhtiari, Reza Safarey, Tayebeh Ghari
International Journal of Pharmaceutical and Health.2021; 13(3): 331. CrossRef
The effect of intangible assets on sustainable growth and firm value – Evidence on intellectual capital investment in companies listed on Bucharest Stock Exchange
Catalin Ionita, Elena Dinu
Kybernetes.2021; 50(10): 2823. CrossRef
AR-GE GİDERLERİ İLE KÂRLILIK VE BÜYÜME ARASINDA NEDENSELLİK İLİŞKİSİ: BIST ÜZERİNE BİR İNCELEME
Mehmet DİKİCİ, Kadir GÜRDAL
Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 1193. CrossRef
R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry
Chih-Yi Su, Yao-Ning Guo, Kuang-Cheng Chai, Wei-Wei Kong
Frontiers in Public Health.2021;[Epub] CrossRef
R&D SPENDING AND FINANCIAL PERFORMANCE: AN INVESTIGATION IN AN EMERGING MARKET
Nasıf ÖZKAN
International Journal of Management Economics and .2021;[Epub] CrossRef
The persistence of current market valuation of future capital investment
Nancy Beneda
Journal of Corporate Accounting & Finance.2020; 31(3): 163. CrossRef
Sustainability assessment of universities as small-scale urban systems: A comparative analysis using Fisher Information and Data Envelopment Analysis
Ning Ai, Marc Kjerland, Cynthia Klein-Banai, Thomas L. Theis
Journal of Cleaner Production.2019; 212: 1357. CrossRef
Analysing future change in the EU's energy innovation system
Yeong Jae Kim, Charlie Wilson
Energy Strategy Reviews.2019; 24: 279. CrossRef
A review of three years' experience of the first pharmacometrics company in Korea
So Jin Lee, Sangil Jeon
Translational and Clinical Pharmacology.2019; 27(4): 149. CrossRef
The impact of inter-industry R&D technology spillover on carbon emission in China
Jianling Jiao, Yufei Yang, Yu Bai
Natural Hazards.2018; 91(3): 913. CrossRef
Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea
Jian Xu, Jae-Woo Sim
Sustainability.2018; 10(9): 3002. CrossRef
R&D Investments, EPO Patent Applications and the Economic Heterogeneity within the EU
Zuzana Potužáková, Jan Öhm
Review of Economic Perspectives.2018; 18(2): 177. CrossRef

First
Prev
Page of 1
Next
Last

Search